User profiles for Nick Devoogdt
DevoogdtICMI VUB Verified email at vub.be Cited by 9712 |
[HTML][HTML] Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells
…, C Abels, S Schoonooghe, G Raes, N Devoogdt… - Nature …, 2016 - nature.com
Self-renewing tissue-resident macrophages are thought to be exclusively derived from
embryonic progenitors. However, whether circulating monocytes can also give rise to such …
embryonic progenitors. However, whether circulating monocytes can also give rise to such …
Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy
B Van de Broek, N Devoogdt, A D'Hollander, HL Gijs… - ACS …, 2011 - ACS Publications
Branched gold nanoparticles are potential photothermal therapy agents because of their large
absorption cross section in the near-infrared window. Upon laser irradiation they produce …
absorption cross section in the near-infrared window. Upon laser irradiation they produce …
Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma
…, C Xavier, J Heemskerk, N Devoogdt… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor characteristics
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …
Nanobodies and their potential applications
G Hassanzadeh-Ghassabeh, N Devoogdt… - …, 2013 - Future Medicine
Nanobodies are recombinant, antigen-specific, single-domain, variable fragments of camelid
heavy chain-only antibodies. The innate supremacy of nanobodies as a renewable source …
heavy chain-only antibodies. The innate supremacy of nanobodies as a renewable source …
Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer
I Vaneycken, N Devoogdt, N Van Gassen… - The FASEB …, 2011 - Wiley Online Library
Accurate determination of tumor human epidermal growth factor receptor 2 (HER2)‐status in
breast cancer patients is possible via noninvasive imaging, provided adequate tracers are …
breast cancer patients is possible via noninvasive imaging, provided adequate tracers are …
Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages
…, T Lahoutte, P De Baetselier, G Raes, N Devoogdt… - Cancer research, 2012 - AACR
Tumor-associated macrophages (TAM) are an important component of the tumor stroma
and exert several tumor-promoting activities. Strongly pro-angiogenic TAMs that reside in …
and exert several tumor-promoting activities. Strongly pro-angiogenic TAMs that reside in …
Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions
…, T Lahoutte, D Fagret, C Ghezzi, N Devoogdt - Circulation …, 2012 - Am Heart Assoc
Rationale: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is
highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies …
highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies …
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer
…, M Keyaerts, C Vincke, N Devoogdt… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Nanobodies are the smallest fully functional antigen-binding antibody fragments possessing
ideal properties as probes for molecular imaging. In this study we labeled the anti–human …
ideal properties as probes for molecular imaging. In this study we labeled the anti–human …
[HTML][HTML] Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody
…, S Muyldermans, V Caveliers, N Devoogdt… - Theranostics, 2014 - ncbi.nlm.nih.gov
RIT has become an attractive strategy in cancer treatment, but still faces important drawbacks
due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. …
due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. …
[HTML][HTML] Immunogenicity risk profile of nanobodies
…, S Denies, B Stijlemans, Y Elkrim, N Devoogdt… - Frontiers in …, 2021 - frontiersin.org
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a
promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess …
promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess …